Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

NeuroBo Pharmaceuticals Completes Enrollment For Single Ascending Dose (SAD) Part 1 Of Phase 1 Trial For Obesity Treatment DA-1726; No Significant Issues Encountered, Enabling Accelerated Start To Multiple Ascending Dose (MAD) Part 2; Top Line Data For SAD Expected In Q3 2024, MAD Data In Q1 2025

Author: Benzinga Newsdesk | August 13, 2024 08:04am

Posted In: NRBO